Vineet Laboratories Ltd

Vineet Laboratories Ltd's board meeting on May 30, 2026, deferred the consideration of the audited standalone financial results for the quarter and financial year ended March 31, 2026, as the Audit Committee did not consider and recommend them. The company will intimate the revised dates for the Audit Committee Meeting and Board Meeting to the Stock Exchange(s) in due course. The trading window, which was closed from April 1, 2026, will remain closed until 48 hours after the declaration of the financial results.

Vineet Laboratories Ltd has scheduled a Board of Directors meeting on May 30, 2026, to consider and approve the Audited Standalone Financial Results for the fourth quarter and financial year ended March 31, 2026. The trading window for dealing in the company's equity shares has been closed from April 01, 2026, until 48 hours after the announcement of the financial results, in compliance with SEBI regulations.

Vineet Laboratories Ltd has released the Monitoring Agency Report issued by Crisil Ratings Limited for the quarter ended March 31, 2026, pertaining to the utilization of funds raised through the Rights Issue. Crisil's report indicates that the proceeds have been utilized towards repayment of loans, purchase of equipment, working capital requirements, and issue expenses. The report declares no deviations from the stated objectives in the offer document.

Vineet Laboratories Ltd has announced the closure of its trading window from 01st April, 2026 till 48 hours after the announcement of Standalone Audited Financial results for the Fourth Quarter and Financial year ending on 31st March, 2026. This closure is in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015 and the Company's Code of Conduct for regulating, monitoring, and reporting trading by Insiders and Code of Practices and Procedures for fair disclosure of Unpublished Price Sensitive Information. The PAN of all the Designated Persons (‘DPs”) and their immediate relatives have been frozen during the period of trading window closure. The date of the Board Meeting for declaration of the Standalone Audited Financial results will be intimated in due course.

Vineet Laboratories Ltd. announced its unaudited standalone financial results for the third quarter and nine months ended on December 31, 2025, in a board meeting held on February 14, 2026. The board also approved and ratified payments towards Quality Control equipment and Purified RO Water equipment for the new production facility. The financial results are available on the company's website and the websites of BSE Limited and National Stock Exchange of India.

Vineet Laboratories Ltd. announced its unaudited standalone financial results for the third quarter and nine months ended on December 31, 2025. The Board of Directors approved the financial results during their meeting on February 14, 2026, along with a limited review report submitted by the statutory auditors. The company also approved and ratified proposed payments towards quality control equipment and purified RO water equipment for the new production facility, which was mentioned in the Letter of Offer dated December 17, 2025. The financial results are available on the company's website and the websites of BSE Limited and National Stock Exchange of India.

Arjun Aggarwal, a shareholder of Vineet Laboratories Ltd, has acquired 21,80,000 Equity shares representing 12.07% of the total issued and paid-up Capital through a Rights Issue. This acquisition makes Arjun Aggarwal a significant shareholder in the company.

Vineet Laboratories Ltd. has announced that its Board of Directors will meet on February 14, 2026, to consider and approve the unaudited standalone financial results for the third quarter ended on December 31, 2025. The meeting is in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015. The trading window for dealing in the equity shares of the company was closed from January 01, 2026, till 48 hours after the announcement of financial results to all designated persons, their immediate relatives, and all connected persons covered under the said Code. The trading window will remain closed till Monday, February 16, 2026.

Vineet Laboratories Ltd. has announced the receipt of trading approvals from BSE and NSE for the equity shares allotted under the Rights Issue of the company. A total of 99,87,258 equity shares have been allotted, which will be listed and admitted to dealings on both exchanges from February 5, 2026. This development is in accordance with the SEBI (LODR), 2015 regulations.

Vineet Laboratories Limited has announced the approval of the Rights Issue Committee of the Board of Directors for the allotment of 99,87,258 Equity Shares on a rights basis. The shares, with a face value of Rs. 10 each, will be issued at an issue price of Rs. 30 per Equity Share, including a premium of Rs. 20 per Equity Share. The allotment is in accordance with the Letter of Offer dated December 17, 2025, and the 'Basis of Allotment' as finalized in consultation with the Registrar to the Issue and approved by the Designated Stock Exchange for the Issue. The issued, subscribed, and paid-up equity share capital of the Company will increase from 9,21,90,080 to 19,20,62,660 post the Rights Issue.